References:
1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.
2. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int 2020;40:998-1004.
3. Labenz C, Toenges G, Wörns M-A, Sprinzl MF, Galle PR, Schattenberg JM. Liver injury in patients with severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis. European Journal of Gastroenterology & Hepatology 9000;Publish Ahead of Print.
4. Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study. Liver Int 2020;40:1321-6.
5. Piano S, Dalbeni A, Vettore E, Benfaremo D, Mattioli M, Gambino CG et al. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. Liver Int 2020.
6. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y et al. COVID-19: Abnormal liver function tests. J Hepatol 2020;73:566-74.
7. Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM et al. Guidelines on the management of abnormal liver blood tests. Gut 2018;67:6-19.
8. Musana KA, Yale SH, Abdulkarim AS. Tests of liver injury. Clin Med Res 2004;2:129-31.
9. China NHCoTPsRo. Diagnosis and Treatment Protocol for COVID-19 Patients (Tentative 8th Edition). 2020.
10. Jiang S, Wang R, Li L, Hong D, Ru R, Rao Y et al. Liver Injury in Critically Ill and Non-critically Ill COVID-19 Patients: A Multicenter, Retrospective, Observational Study. Front Med (Lausanne) 2020;7:347.
11. Bertolini A, van de Peppel IP, Bodewes F, Moshage H, Fantin A, Farinati F et al. Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis. Hepatology 2020.
12. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 2020;5:428-30.
13. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4.
14. Muhovic D, Bojovic J, Bulatovic A, Vukcevic B, Ratkovic M, Lazovic R et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int 2020.
15. Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis. Liver Int 2020;40:1316-20.
16. Napodano C, Pocino K, Stefanile A, Marino M, Miele L, Gulli F et al. COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. Scand J Immunol 2020:e12977.
17. D’Antiga L. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transpl 2020;26:832-4.
18. Qi X, Wang J, Li X, Wang Z, Liu Y, Yang H et al. Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China. Hepatol Int 2020;14:478-82.
19. Sharma P, Kumar A. Metabolic dysfunction associated fatty liver disease increases risk of severe Covid-19. Diabetes Metab Syndr 2020;14:825-7.
20. Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest 2020;50:e13338.
21. Mahamid M, Nseir W, Khoury T, Mahamid B, Nubania A, Sub-Laban K et al. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study. Eur J Gastroenterol Hepatol 2020.